Fanconi renotubular syndrome 2
MONDO:0013247
Any Fanconi syndrome in which the cause of the disease is a mutation in the SLC34A1 gene.
Disease research snapshot
CureCurrent currently links 1 distinct registered clinical trials to Fanconi renotubular syndrome 2 through its MONDO disease mappings. 1 of those studies have the registry status “recruiting” (100%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.
The leading sponsor shown in this linked dataset is UK Kidney Association, associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.
Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Fanconi renotubular syndrome 2
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
1 shownDrugs being studied
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.